- Home
- Publications
- Publication Search
- Publication Details
Title
Current status and novel strategy of CML
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 113, Issue 5, Pages 624-631
Publisher
Springer Science and Business Media LLC
Online
2021-03-30
DOI
10.1007/s12185-021-03127-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Outcomes of Patients with Chronic Myeloid Leukemia with Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome
- (2021) Kiyomi Morita et al. Clinical Lymphoma Myeloma & Leukemia
- Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
- (2021) Hagop M. Kantarjian et al. LEUKEMIA
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
- (2020) Abhishek Maiti et al. ACTA HAEMATOLOGICA
- Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.
- (2020) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemia
- (2020) Maro Ohanian et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India
- (2020) Abhijit Phukan et al. ANNALS OF HEMATOLOGY
- The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
- (2020) Mahran Shoukier et al. HAEMATOLOGICA
- The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
- (2020) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
- (2019) Koji Sasaki et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
- (2019) Kiran Naqvi et al. CANCER
- Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
- (2019) Iman Abou Dalle et al. Cancer Medicine
- Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
- (2019) Timothy P. Hughes et al. BLOOD
- Sudden blastic transformation in treatment‐free remission chronic myeloid leukaemia
- (2019) Mansour Alfayez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
- (2016) P. Jain et al. BLOOD
- Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
- (2016) W. Wang et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
- (2016) Preetesh Jain et al. BRITISH JOURNAL OF HAEMATOLOGY
- A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
- (2016) Koichi Takahashi et al. CANCER
- Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction
- (2016) Koji Sasaki et al. Clinical Lymphoma Myeloma & Leukemia
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
- (2015) Alice Fabarius et al. ANNALS OF HEMATOLOGY
- Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
- (2015) Koji Sasaki et al. CANCER
- Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
- (2015) M Pfirrmann et al. LEUKEMIA
- Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
- (2015) Koji Sasaki et al. Lancet Haematology
- Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
- (2015) Preetesh Jain et al. Lancet Haematology
- Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
- (2014) Michele Baccarani et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
- (2012) J. P. Radich et al. BLOOD
- BCR-ABL1transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib
- (2012) Dennis D. Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
- (2011) A. Fabarius et al. BLOOD
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
- (2011) J. Hasford et al. BLOOD
- The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
- (2011) E. Jabbour et al. BLOOD
- Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
- (2010) Elias Jabbour et al. CANCER
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
- (2009) M. C. Muller et al. BLOOD
- Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
- (2009) A. Quintas-Cardama et al. BLOOD
- Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
- (2009) Michele Baccarani et al. BLOOD
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
- (2008) S. J. Lee et al. BLOOD
- Molecular monitoring in chronic myeloid leukemia
- (2008) Elias Jabbour et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started